BUY Aurobindo Pharma — Kunal Saraogi, 06 Jul 2026

byKunal SaraogiHorizon: Swing (≤2wk)6 Jul 2026via Zee Business (Live)

Entry₹1,615Stated

Target₹1,680

Stop loss₹1,590-1.55% risk

Exit₹1,5906 Jul 2026, 3:15 pm

Stop-loss hit-1.55%

Follow Kunal Saraogi for new calls(32% target hit, 28 closed calls)Get alerts Watch AUROPHARMA for new buy/sell callsGet alerts See 2 active Swing calls on AUROPHARMA See 128 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 8 Sept, 9:21 am IST

5 supporting0 opposing

Supports the BUY call (5)

2 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·3 Jul · 3d ago

Aurobindo Pharma USA Inc., a subsidiary of Aurobindo Pharma, has completed the acquisition of Lannett.

NSE · Acquisition·30 Jun · 6d ago

Aurobindo Pharma Ltd has announced the completion of an acquisition.

BSE · Company Update·25 Jun · 1w ago

Aurobindo Pharma has completed the execution of a solar power purchase agreement and acquired a 26% stake in Swarnaakshu Solar Power Private Limited for Rs. 52 lakhs. The company plans further investm

NSE · Acquisition·25 Jun · 1w ago

1 advisor has an active short-term BUY call on this stock

Advisor consensus · adjacent horizon·6 Apr · 3mo ago

Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.